EMA recommends extending the Mpox vaccine to 12-17 year olds

The European Medicines Agency (EMA) has recommended extending the indication for the Mpox vaccine Imvanex to include adolescents aged 12-17. The preliminary findings of a study conducted by the Committee for Medicinal Products for Human Use (CHMP) of the EMA, which examined the vaccine’s capacity to elicit an immune response in 315 adolescents and 211 adults, indicated that the immune response observed in adolescents was comparable to that observed in adults. Based on the data presented, the safety profile of Imvanex in adolescents was consistent with that observed in adults, and no additional risks were identified.